Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Ketamine for Acute Traumatic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients aged 18-70 years, with mild to moderate blunt trauma (sustained in road, workplace and home accidents) causing moderate to severe pain (≥ 80mm score on a 100mm Visual Analog Scale=VAS) were eligible for participation in the study. Inclusion criteria also included a Glasgow Coma Score (GCS) of 15, body weight of 50-110 kg, systolic blood pressure of 90-160 mmHg, heart rate \<100 bpm. Patients were also required to have an American Society of Anesthesiologists (ASA) score of 1 or 2, deny head injury, and deny regular use or use of opiates.~Exclusion Criteria:~Any analgesia received within the prior 3 hours, allergic sensitivity to morphine or ketamine, a large meal ingested within the previous hour, pregnancy, deviated nasal septum or trauma to the nose, and a history of a psychiatric condition. Despite evidence that ketamine does not exacerbate intracranial hemorrhage in patients with head trauma, patients with head injury complaining of loss of consciousness, dizziness, vomiting, or nausea were excluded as well.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IN Ketamine (Type: EXPERIMENTAL): A single administration of 1 mg/kg ketamine hydrochloride delivered in an intranasal route using an atomizer
- IM Morphine (Type: ACTIVE_COMPARATOR): A single administration of 0.15 mg/kg intramuscular morphine
- IV Morphine (Type: ACTIVE_COMPARATOR): A single administration of 0.1 mg/kg slow intravascular bolus of morphine.

Based on this trial design, predict the completion outcome and termination type (if applicable).